Ilse Hoffman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Ilse Hoffman has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Severine Vermeire
Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
2 shared publications A D'Hoore
Departments of Gastroenterology, Abdominal Surgery, and Paediatric Gastroenterology, University Hospital Leuven, Belgium
1 shared publication- Anders Lindblad
Queen Silvia Children's Hospital, Gothenburg, Sweden
1 shared publication - Birgitta Strandvik
CLINTEC, Karolinska Institutet NOVUM, Stockholm, Sweden
1 shared publication - Bruno Hauser
Paediatric Gastroenterology, Hepatology and Nutrition, Universitair Ziekenhuis Brussel - Vrije Universiteit Brussel (VUB), Brussels, Belgium
1 shared publication - David Cassiman
Department of Gastroenterology-Hepatology and Metabolic Center, Catholic University Leuven, Leuven, Belgium
1 shared publication
Latest Publications
- 12 June 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (3) , 447-455
Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease
Objectives: Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX biosimilar CT‐P13 in IBD. Methods: In this single‐center observational study, we investigated all pediatric patients with IBD on maintenance IFX therapy who were switched from originator (Remicade®) to CT‐P13 (Inflectra®, switch A in cohort A) in 2018 and to CT‐P13 (Remsima®, switch B in cohort B) in 2022. Cohort C includes patients who underwent both switches. Demographics, disease activity, remission rates and IFX trough levels were collected from 6 months before to 6 months after each switch. Results: A total of 42 children (cohort A) and 44 children (cohort B) had a single switch to CT‐P13; 14 (cohort C) had multiple switches. Median IFX trough concentration was 5.7 ([3.8–9.3) and 9.0 (6.2–11.7) µg/mL versus 6.5 (3.9–8.6) and 9.22 (7.9–10.5) µg/mL 6 months after switch in cohort A and B and 4.3 (3.4–10.9) versus 7.9 (6.9–9.7) and 9.3 (8.3–10.3) versus 9.4 (7.9–10.6) for respectively both switches in cohort C (all p > 0.05). Antibodies to IFX developed in one patient post‐switch. Clinical/biological remission rates remained stable. No clinically significant changes in inflammatory biomarkers and safety profile were noted before and after switch. Conclusions: Switching to CT‐P13 biosimilars appears to maintain remission without relevant changes in pharmacokinetics, disease activity, or adverse events in pediatric patients with IBD. Further studies are required.
- 12 June 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 83 (3) , 447-455
Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease
Objectives: Infliximab (IFX) is highly effective but costly, driving the adoption of biosimilars. Data on switching from originator IFX to biosimilars in pediatric inflammatory bowel disease (IBD) patients remain limited. This study evaluated the safety and efficacy of switching from originator IFX to IFX biosimilar CT‐P13 in IBD. Methods: In this single‐center observational study, we investigated all pediatric patients with IBD on maintenance IFX therapy who were switched from originator (Remicade®) to CT‐P13 (Inflectra®, switch A in cohort A) in 2018 and to CT‐P13 (Remsima®, switch B in cohort B) in 2022. Cohort C includes patients who underwent both switches. Demographics, disease activity, remission rates and IFX trough levels were collected from 6 months before to 6 months after each switch. Results: A total of 42 children (cohort A) and 44 children (cohort B) had a single switch to CT‐P13; 14 (cohort C) had multiple switches. Median IFX trough concentration was 5.7 ([3.8–9.3) and 9.0 (6.2–11.7) µg/mL versus 6.5 (3.9–8.6) and 9.22 (7.9–10.5) µg/mL 6 months after switch in cohort A and B and 4.3 (3.4–10.9) versus 7.9 (6.9–9.7) and 9.3 (8.3–10.3) versus 9.4 (7.9–10.6) for respectively both switches in cohort C (all p > 0.05). Antibodies to IFX developed in one patient post‐switch. Clinical/biological remission rates remained stable. No clinically significant changes in inflammatory biomarkers and safety profile were noted before and after switch. Conclusions: Switching to CT‐P13 biosimilars appears to maintain remission without relevant changes in pharmacokinetics, disease activity, or adverse events in pediatric patients with IBD. Further studies are required.
- 1 July 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (11) , 3000-3012
Discrepancies in the Diagnosis, Treatment and Prevention of Cow Milk Allergy Among Paediatricians
Aim: Different scientific societies published guidelines and recommendations on the diagnosis, treatment and prevention of cow's milk allergy (CMA). We aimed to compare the guidelines of the European Society of Gastroenterology, Hepatology and Nutrition (ESPGHAN) with the practices of Flemish paediatricians. Methods: During 2023, 73 statements of the ESPGHAN CMA‐position paper were submitted to 50 Flemish general paediatricians, who voted on these statements with the same methodology. If more than 25% of the paediatricians disagreed with the statements approved by ESPGHAN, the statements were considered ‘rejected’. Results: The applicability of guidelines might be limited since Flemish paediatricians rejected 25/73 (34%) of the statements endorsed in the ESPGHAN manuscript. Conclusion: The opinions of general paediatricians and ESPGHAN authors regarding the diagnosis, management and prevention of CMA differ substantially. Further research should investigate if this is due to lack of knowledge and comprehension of the available information, due to lack of applicability or application of the recommendations.
- 1 July 2025
- Published by Wiley in Acta Paediatrica
- Vol. 114 (11) , 3000-3012
Discrepancies in the Diagnosis, Treatment and Prevention of Cow Milk Allergy Among Paediatricians
Aim: Different scientific societies published guidelines and recommendations on the diagnosis, treatment and prevention of cow's milk allergy (CMA). We aimed to compare the guidelines of the European Society of Gastroenterology, Hepatology and Nutrition (ESPGHAN) with the practices of Flemish paediatricians. Methods: During 2023, 73 statements of the ESPGHAN CMA‐position paper were submitted to 50 Flemish general paediatricians, who voted on these statements with the same methodology. If more than 25% of the paediatricians disagreed with the statements approved by ESPGHAN, the statements were considered ‘rejected’. Results: The applicability of guidelines might be limited since Flemish paediatricians rejected 25/73 (34%) of the statements endorsed in the ESPGHAN manuscript. Conclusion: The opinions of general paediatricians and ESPGHAN authors regarding the diagnosis, management and prevention of CMA differ substantially. Further research should investigate if this is due to lack of knowledge and comprehension of the available information, due to lack of applicability or application of the recommendations.
- Open Access
- 1 June 2019
- Published by Elsevier in Pediatrics & Neonatology
- Vol. 60 (3) , 261-269
Neonatal factors predictive for respiratory and gastro-intestinal morbidity after esophageal atresia repair
- 1 June 2019
- Published by Elsevier in Pediatrics & Neonatology
- Vol. 60 (3) , 261-269
Open AccessNeonatal factors predictive for respiratory and gastro-intestinal morbidity after esophageal atresia repair
- 10 December 2017
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 17 (2) , 185-196
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease
Introduction: Although anti-TNF therapy has changed the scenery of pediatric inflammatory bowel diseases (IBD) immensely, there are still patients with an unfortunate outcome. Approximately one third of patients that initially respond to anti-TNF therapy will lose that response over time and need treatment optimization. Loss of response (LOR) is a big concern in IBD management and especially among pediatric patients where treatment options are more limited than in adults. In children it is even more important to sustain response with minimal toxicity. Therapeutic drug monitoring (TDM) is proposed as a tool to reach this goal. Areas covered: This review focuses on the importance of TDM of anti-TNF and the role TDM has in clinical practice of pediatric IBD. Expert opinion: Although TDM is not yet widely used in pediatric IBD, the available literature suggests it to be a promising tool, especially in patients with LOR to anti-TNF. There is increasing evidence that also in children, higher anti-TNF drug levels are associated with sustained response, and likewise low or undetectable trough levels increase the likelihood of LOR. TDM-based treat to target strategies are being designed in adult studies, but more prospective studies also in pediatric IBD populations looking at the role of proactive testing are needed.
- 10 December 2017
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 17 (2) , 185-196
Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease
Introduction: Although anti-TNF therapy has changed the scenery of pediatric inflammatory bowel diseases (IBD) immensely, there are still patients with an unfortunate outcome. Approximately one third of patients that initially respond to anti-TNF therapy will lose that response over time and need treatment optimization. Loss of response (LOR) is a big concern in IBD management and especially among pediatric patients where treatment options are more limited than in adults. In children it is even more important to sustain response with minimal toxicity. Therapeutic drug monitoring (TDM) is proposed as a tool to reach this goal. Areas covered: This review focuses on the importance of TDM of anti-TNF and the role TDM has in clinical practice of pediatric IBD. Expert opinion: Although TDM is not yet widely used in pediatric IBD, the available literature suggests it to be a promising tool, especially in patients with LOR to anti-TNF. There is increasing evidence that also in children, higher anti-TNF drug levels are associated with sustained response, and likewise low or undetectable trough levels increase the likelihood of LOR. TDM-based treat to target strategies are being designed in adult studies, but more prospective studies also in pediatric IBD populations looking at the role of proactive testing are needed.
- Open Access
- 10 January 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (3) , 1064-1065
Noncirrhotic Presinusoidal Portal Hypertension Is Common in Cystic Fibrosis–Associated Liver Disease Δ
- 10 January 2011
- Published by Wolters Kluwer Health in Hepatology
- Vol. 53 (3) , 1064-1065
Open AccessNoncirrhotic Presinusoidal Portal Hypertension Is Common in Cystic Fibrosis–Associated Liver Disease Δ
- Open Access
- 1 July 2009
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 15 (7) , 1062-1070
Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis
Background. Recent reports suggest that the preoperative use of infliximab (IFX) increases postoperative infectious complications in patients with ulcerative co
- 1 July 2009
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 15 (7) , 1062-1070
Open AccessCorticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis
Background. Recent reports suggest that the preoperative use of infliximab (IFX) increases postoperative infectious complications in patients with ulcerative co